Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
In This Article:
Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome study.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome study.